Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Long-Term Investments (2016 - 2025)

Historic Long-Term Investments for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $22.1 million.

  • Ultragenyx Pharmaceutical's Long-Term Investments fell 8913.42% to $22.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.1 million, marking a year-over-year decrease of 8913.42%. This contributed to the annual value of $135.0 million for FY2024, which is 3246.46% down from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Long-Term Investments is $22.1 million, which was down 8913.42% from $51.5 million recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Long-Term Investments peaked at $258.9 million during Q4 2021, and registered a low of $22.1 million during Q3 2025.
  • Its 5-year average for Long-Term Investments is $131.0 million, with a median of $128.0 million in 2021.
  • Its Long-Term Investments has fluctuated over the past 5 years, first surged by 304727.14% in 2021, then tumbled by 8913.42% in 2025.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Long-Term Investments stood at $258.9 million in 2021, then crashed by 42.47% to $149.0 million in 2022, then surged by 34.19% to $199.9 million in 2023, then tumbled by 32.46% to $135.0 million in 2024, then tumbled by 83.65% to $22.1 million in 2025.
  • Its last three reported values are $22.1 million in Q3 2025, $51.5 million for Q2 2025, and $68.6 million during Q1 2025.